Low incidence of port-site XXXX after robotic assisted surgery for @entity1204 staging: descriptive analysis.

@entity1 @entity5 @entity3 @entity1204
The purpose of this study was to evaluate the incidence and characteristics of @entity1 with port-site @entity3 following robotic assisted surgery for gynecological @entity5 . @entity1 who underwent robotic assisted total laparoscopic hysterectomy and surgical staging at a single institution from November 2006 through November 2011 were retrospectively identified. Medical records were reviewed and the following information was extracted: diagnosis, histology, @entity5 extension, procedure, complications and post-surgical intervention. Port-site @entity3 were differentiated between isolated and not isolated. All @entity3 were confirmed with biopsy and treated with chemotherapy and radiotherapy as indicated. Four hundred forty-six @entity1 with @entity1204 were identified who had undergone robotic assisted hysterectomy and staging. Eight @entity1 were converted to laparotomy and excluded from the study. Of 438 @entity1 , 384 @entity1 were diagnosed with early stages (stages 1 and 2), and 54 were diagnosed with advanced stages (stages 3 and 4). A total of 332 @entity1 underwent pelvic lymphadenectomy regardless of the @entity1204 ; of those, 283 with early stage disease underwent pelvic lymphadenectomy, while 49 with advanced stage disease underwent pelvic lymphadenectomy. One hundred seventy-six @entity1 received adjuvant treatment after surgical staging. Four @entity1 were identified with port-site @entity3 (0.9  %), two @entity1 were reported as isolated @entity3 . The mean @entity1 age was 63 and mean BMI was 37  kg/m(2). The incidence of port-site @entity3 is low after robotic assisted surgery for treatment of @entity1204 (0.9  %). There is no clear risk factor for development of port-site @entity3 or easily identifiable prevention.
